The expanding role of prophylaxis with recombinant activated factor VII.

about

The expanding role of prophylaxis with recombinant activated factor VII.

Item

http://www.wikidata.org/entity/Q43051388

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh-hant

name

The expanding role of prophylaxis with recombinant activated factor VII.

@en

The expanding role of prophylaxis with recombinant activated factor VII.

@nl

type

Item

label

The expanding role of prophylaxis with recombinant activated factor VII.

@en

The expanding role of prophylaxis with recombinant activated factor VII.

@nl

prefLabel

The expanding role of prophylaxis with recombinant activated factor VII.

@en

The expanding role of prophylaxis with recombinant activated factor VII.

@nl

P1476

The expanding role of prophylaxis with recombinant activated factor VII.

@en

P2093

Annarita Tagliaferri

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical use of recombinant FVIIa (rFVIIa).

New products for managing inhibitors to coagulation factors: a focus on recombinant factor VIIa concentrate.

Prophylaxis in haemophilia patients with inhibitors.

Prophylaxis in congenital hemophilia with inhibitors: the role of recombinant activated factor VII.

Innovative use of recombinant activated factor VII during physical rehabilitation in an Italian child with Glanzmann's thromboasthenia

NovoSeven in immune tolerance therapy.

Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors.

Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres.

Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors.

Prophylaxis for severe haemophilia: clinical challenges in the absence as well as in the presence of inhibitors.

P304

12-13

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.2450/2012.0061-12

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Massimo Franchini

P577

2012-07-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22790270

http://www.w3.org/2001/XMLSchema#string

P932

3557471

http://www.w3.org/2001/XMLSchema#string